The FDA approved Merck's Welireg (belzutifan) plus Keytruda (pembrolizumab) as adjuvant therapy for adults with clear cell renal cell carcinoma (ccRCC) at risk of recurrence after surgery, based on the Phase III LITESPARK-022 trial in 1,841 post-nephrectomy patients. At a prespecified interim analysis, the regimen delivered a 28% disease-free survival benefit, with 186 events vs. 246 for Keytruda plus placebo; median DFS was not reached in either arm and OS data remain immature.

Why It Matters To Oncology

• The approval expands Merck's footprint in Renal Cell Carcinoma (RCC) by moving Welireg earlier in the treatment paradigm, from previously treated advanced disease into the adjuvant setting.

• It also broadens the post-nephrectomy toolkit for high-risk ccRCC, including patients with intermediate-high or high recurrence risk and those with resected metastases and no evidence of disease.

• The label also covers Keytruda Qlex, the subcutaneous pembrolizumab formulation, potentially adding administration flexibility for clinicians and infusion centers.

The Financials

• The FDA decision came after a priority review, underscoring the commercial and clinical importance of earlier-stage kidney cancer.

• For Merck, this is another kidney cancer win for Keytruda and builds on Welireg's existing RCC franchise following its 2023 approval in previously treated advanced RCC.

• The move positions Merck to capture more of the adjuvant RCC market, where durable recurrence prevention could support broad uptake if longer-term data hold.

What They're Saying

• Merck is leaning on the LITESPARK-022 data to argue the combination can reduce recurrence risk after surgery in ccRCC.

• Still, some experts previously told FirstWord they planned to stick with Bristol Myers Squibb's Opdivo-based immuno-oncology combinations in RCC because of ongoing uncertainty around sequencing.

• That makes real-world adoption likely to hinge on how clinicians weigh the DFS signal against unresolved OS and treatment-ordering questions.

What's Next

• Overall survival follow-up from LITESPARK-022 will be closely watched, given the interim analysis was not mature for OS.

• Clinicians will also look for more detail on tolerability, duration of therapy, and which postoperative risk groups derive the clearest benefit.

• The key strategic question: whether this adjuvant combination reshapes sequencing in RCC or remains a selective option alongside established PD-1 and PD-1/VEGF regimens.